Armen Asatryan

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Stefan Zeuzem, Graham R. Foster, Stanley Wang et al. · New England Journal of Medicine · 2018 · 437 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

Paul Y. Kwo, Fred Poordad, Armen Asatryan et al. · Journal of Hepatology · 2017 · 297 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +16

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

Fred Poordad, Franco Felizarta, Armen Asatryan et al. · Hepatology · 2017 · 201 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure

Fred Poordad, Stanislas Pol, Armen Asatryan et al. · Hepatology · 2017 · 139 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis

Mohamed‐Eslam F. Mohamed, Heidi S. Camp, Ping Jiang et al. · Clinical Pharmacokinetics · 2016 · 116 citations

Medicine, Pharmacokinetics, Pharmacology +12